CCO Infectious Disease Podcast

EASL 2020 Virtual Conference: Rapid Audio Recap

Episode Summary

Hear insights from hepatology expert, Stefan Zeuzem, MD, on some of the most important new viral hepatitis data reported at the 2020 Digital International Liver Congress, organized by the European Association for the Study of the Liver. The studies highlighted in this podcast focus on HCV elimination and the treatment of HCV, HBV, and HDV infection.

Episode Notes

In this episode, Dr. Stefan Zeuzem discusses results from key viral hepatitis studies reported at the 2020 Digital International Liver Congress, organized by the European Association for the Study of the Liver, including important findings from the following reports:

• Update on global progress toward HCV elimination goals
• SToP-C: HCV treatment-as-prevention in Australian prisons
• SHARED cohort: correlates of treatment failure with GLE/PIB or SOF/VEL/VOX
• Trio Health: retreating HCV with GLE/PIB or SOF/VEL/VOX after DAA failure
• Stop-NUC: discontinuation of long-term nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic HBV infection
• High-dose bulevirtide for chronic HBV/HDV coinfection
• Summary of select agents under early-phase investigation for HBV treatment

Presenter:

Stefan Zeuzem, MD
Professor of Medicine  
Chief, Department of Medicine I  
JW Goethe University Hospital  
Frankfurt, Germany

Content based on a CME program supported by an independent educational grant from Gilead Sciences.

Link to full program:
https://bit.ly/33nkRUI